Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Feb 28, 2019 (8 years ago)

Losartan Potassium Tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90 count (NDC 31722-702-30), c) 1000 count (NDC 31722-702-10) bottles, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar -509 301, India

Affected NDCs 31722-0702-10 31722-0702-30

Compare with the code on your package — it is the most precise check available.

Drug: Losartan Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Losartan Potassium
NDC 31722-0702
100 mg/1 Tablet, Film Coated
Oral
Camber Pharmaceuticals, Inc. Rx
Recalling firm
Camber Pharmaceuticals Inc
NDC code
31722-702-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1043-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Losartan recalls

See all

Other recalls by Camber Pharmaceuticals Inc

All 2019 recalls
Class I · High risk

Atovaquone Oral Suspension USP

Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.

Ongoing Microbial contamination Camber Pharmaceuticals Inc. NDC 31722-629-21 D-0567-2023
Class III · Low risk

Lacosamide Oral Solution

Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Terminated Failed specification Camber Pharmaceuticals, Inc NDC 31722-627-26 D-0094-2023
Class II · Moderate risk

Losartan Potassium Tablets USP

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient

Ongoing Nitrosamine impurity Camber Pharmaceuticals Inc NDC 31722-701-30 D-1042-2019
Class II · Moderate risk

Losartan Potassium Tablets USP

CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient

Ongoing Nitrosamine impurity Camber Pharmaceuticals Inc NDC 31722-700-90 D-1041-2019